Fact Source: DS Investment & Securities Report (Published on July 2, 2026) Investment Rating & Target Price: BUY / KRW 300,000 Core Momentum: Superior cost-structure advantages in the bio business and expected tailwinds from global anti-dumping duties
━━━━━━━━━━━━━━━━━━━━━━
📊 1. [Valuation & Investment Indicator Analysis]
Key Investment Guidelines
- Investment Rating: BUY (Maintained)
- Target Price: KRW 300,000 (Maintained)
- Current Price (As of July 1, 2026): KRW 187,800
Annual Financial Facts & Forecast Key Metrics
- 2024: Revenue KRW 27,240 billion, Operating Profit KRW 1,452 billion, Net Profit (Controlling Interest) KRW 132 billion, ROE 1.8%, PER 30.2x, PBR 0.5x
- 2025: Revenue KRW 27,343 billion, Operating Profit KRW 1,192 billion, Net Profit (Controlling Interest) KRW -571 billion (Turned Negative), ROE -7.7%, PER -5.3x, PBR 0.5x
- 2026 (F): Revenue KRW 28,704 billion, Operating Profit KRW 1,280 billion, Net Profit (Controlling Interest) KRW 351 billion (Turned Positive), ROE 5.1%, PER 8.1x, PBR 0.5x
- 2027 (F): Revenue KRW 29,534 billion, Operating Profit KRW 1,326 billion, Net Profit (Controlling Interest) KRW 370 billion, ROE 5.4%, PER 7.7x, PBR 0.4x
━━━━━━━━━━━━━━━━━━━━━━
🚀 2. [Market Opportunities (TAM) & Detailed Earnings Forecasts]
2Q26 Earnings Outlook & Divisional Trends
- Consolidated Group Estimates: 2Q26 consolidated revenue is projected at KRW 7.0 trillion (+4% YoY) with an operating profit of KRW 278.9 billion (-9% YoY), tracking in line with market forecasts of KRW 277.8 billion.
- Food Divisions: Domestic food revenue is estimated at KRW 1.3 trillion (+1% YoY), where steady growth in processed goods is softened by lower commercial ingredients pricing. Overseas food revenue is modeled at KRW 1.4 trillion (+7% YoY), supported by core items like frozen dumplings and ready-to-eat rice in the US alongside double-digit momentum in Europe and APAC, despite higher promotion and input costs.
- Bio Division: Revenue is expected to reach KRW 1.1 trillion (+7% YoY), showcasing increased profit contributions led by methionine sales and high-margin specialty solutions.
Second-Half Growth Catalysts & Macro Factors
- Amino Acid Market Dynamics: Following last year’s margin compression from Chinese supply inflows into Europe, the bio unit faces a low baseline comparison. Anticipated anti-dumping duties on Chinese lysine in the US and Brazil during the second half are set to serve as a strong operational catalyst.
- Mitigating Headwinds: To tackle high currency exposure, elevated grain benchmarks, and shipping inflation, the enterprise focuses on infrastructure streamlining and structural optimization to fortify long-term returns.
━━━━━━━━━━━━━━━━━━━━━━
📝 Editor’s Comment
- CJ CheilJedang’s current equity valuation sits near its historical floor, indicating that domestic demand and margin anxieties are fully priced in. The defining narrative here is portfolio resilience rather than cyclical decay. The company’s specialized bio business—bolstered by a structurally defensive cost framework—is successfully absorbing the structural inflation weighing on the food manufacturing segments. As global trade actions restructure the pricing environment for amino acids in the second half, the resulting cash-flow expansion paired with proactive corporate restructuring should spark a meaningful re-rating of its compressed valuation multiples.
━━━━━━━━━━━━━━━━━━━━━━
📢 Disclaimer & Source
Source
This content has been restructured and newly generated based on the financial facts and data points from officially published securities research reports.
Investment Risk Warning
This information is provided for informational and educational purposes only. Under no circumstances does it constitute financial advice, or a solicitation or recommendation to buy or sell any specific securities. All investment decisions and subsequent financial liabilities rest entirely with the individual investor.
Contact
Compliance & Copyright Inquiries
ksb220805@gmail.com
🔥 Bulls vs Bears, drop your analysis in the comments!
